Scientists in China have developed a phosphodiesterase-5 (PDE5) inhibitor for pulmonary arterial hypertension (PAH) that reduced disease severity in a rat model of PAH. The scientists detailed the development and testing of the treatment, CPD1, in a study that also shed light on the molecular mechanisms through which the…
Advocates worldwide are gearing up for World Pulmonary Hypertension Day on May 5, focusing this year on the critical role of clinical research. Led by PHA Europe, the annual event seeks to raise awareness and improve the lives of those living with pulmonary hypertension (PH), a condition…
Corvista Health will collaborate with Mayo Clinic to evaluate whether its non-invasive Corvista-PH test can improve the detection, risk stratification, and referral accuracy for people with suspected pulmonary hypertension (PH). “Collaborating with Mayo Clinic represents a defining moment for CorVista and for the advancement of pulmonary hypertension diagnostics,”…
Irregular heart rhythms such as atrial fibrillation, which can make the heart beat too fast, and atrial flutter, which causes the heart to beat out of sync, are relatively common in people with pulmonary arterial hypertension (PAH), a new study in the U.S. suggests. Both types of irregular heart rhythms,…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
